

AMENDMENTS TO THE CLAIMS

- 1-5. (Canceled)
6. (Withdrawn) The method of Claim 5, further comprising e)administering said purified encapsidated second vector to a host cell.
7. (Withdrawn) The method of Claim 6, wherein said administering is under conditions such that said nucleotide sequence of interest in said encapsidated second vector is expressed.
8. (Withdrawn) The method of Claim 6, wherein said host is a cultured cell.
9. (Withdrawn) The method of Claim 6, wherein said host cell is comprised in a mammal.
10. (Withdrawn) The method of Claim 9, wherein said mammal is selected from mouse and human.
11. (Currently Amended) The method for producing the recombinant vector of Claim [[2]] 12, wherein expression of one or more Rep proteins is inducible.
12. (Previously Presented) A method for producing a recombinant vector comprising:
- a) providing:
 - i) a first recombinant vector, comprising in operable combination:
 - 1) a nucleotide sequence of interest having a 5' end and a 3' end;
 - 2) left and right inverted terminal repeats of adenovirus flanking said nucleotide sequence of interest;
 - 3) adenovirus packaging sequence linked to one of said inverted terminal repeats; and
 - 4) a first adeno-associated virus terminal repeat sequence operably linked to said 3' end of said nucleotide sequence of

interest, wherein said first vector lacks a second adeno-associated virus terminal repeat sequence, and lacks one or more adenovirus early gene regions selected from E1, E2, E3, and E4 gene regions;

- ii) a cell capable of expressing one or more Rep proteins; and
 - iii) helper adenovirus;
- b) introducing said first vector and genome of said helper adenovirus into said cell to produce a transformed cell; and
- c) culturing said transformed cell under conditions such that said transformed cell expresses said one or more Rep proteins, and a second vector is produced, said second vector selected from:
- i) a vector, comprising in operable combination:
 - 1) adeno-associated virus terminal repeat-DD sequence;
 - 2) first and second inverted copies of a nucleotide sequence of interest flanking said adeno-associated virus terminal repeat-DD sequence;
 - 3) left and right inverted terminal repeats of adenovirus flanking said first and second inverted copies of said nucleotide sequence of interest; and
 - 4) an adenovirus packaging sequence linked to one of said inverted terminal repeats, and
 - ii) a vector, comprising in operable combination:
 - 1) a nucleotide sequence of interest having a 5' end and a 3' end;
 - 2) left and right inverted terminal repeats of adenovirus flanking said nucleotide sequence of interest; and
 - 3) an adenovirus packaging sequence linked to one of said inverted terminal repeats.

13. (Previously Presented) The method for producing the recombinant vector of Claim 12, wherein said cell lacks expression of said one or more adenovirus early gene regions which are lacking from said first vector.

14-19. (Canceled)

20. (New) The method of Claim 12, wherein said cell comprises a primary cell.

21. (New) The method of Claim 20, wherein said primary cell is selected from the group consisting of mouse cells and human cells.

22. (New) The method of Claim 12, wherein said cell comprises a cell line.

23. (New) The method of Claim 22, wherein said cell line is selected from the group consisting of a HeLa cell line, an A540-derived cell line, a 293-derived cell line, a HepG2-derived cell line, a COS1-derived cell line, an HMEC-derived cell line, a KB-derived cell line, a JW-22-derived cell line, a Neo6-derived cell line and a C12-derived cell line.